Processing

Please wait...

Settings

Settings

Goto Application

1. CA3112051 - PRO-ADRENOMEDULLIN OR FRAGMENT THEREOF IN PATIENTS INFECTED WITH CORONA VIRUS AND TREATMENTS WITH BINDER AGAINST ADRENOMEDULLIN

Office
Canada
Application Number 3112051
Application Date
Publication Number 3112051
Publication Date 16.09.2021
Publication Kind A1
IPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
G16B 20/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 25/10
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
25ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
10Gene or protein expression profiling; Expression-ratio estimation or normalisation
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
26against hormones
G01N 33/48
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors ; ; against growth regulators
C07K 2317/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
10characterized by their source of isolation or production
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
Applicants SPHINGOTEC GMBH
ADRENOMED AG
Priority Data 20163406.0 16.03.2020 EP
20179738.8 12.06.2020 EP
21153847.5 27.01.2021 EP
62/990,171 16.03.2020 US
63/015,102 24.04.2020 US
63/142,370 27.01.2021 US
Title
(EN) PRO-ADRENOMEDULLIN OR FRAGMENT THEREOF IN PATIENTS INFECTED WITH CORONA VIRUS AND TREATMENTS WITH BINDER AGAINST ADRENOMEDULLIN
(FR) PRO-ADRENOMEDULLINE OU FRAGMENT CONNEXE DANS LES PATIENTS INFECTES PAR LA MALADIE A CORONAVIRUS ET TRAITEMENTS AU MOYEN DE LIANTS CONTRE L'ADRENOMEDULLINE
Abstract
(EN)
Subject matter of the present invention is a method for (a) diagnosing or
predicting the risk of
life-threatening deterioration or an adverse event or (b) prognosing the
severity or (c) predicting
or monitoring the success of a therapy or intervention in a patient infected
with a Corona virus,
the method comprising:
= determining the level of pro-Adrenomedullin (SEQ ID No. 31) or fragment
thereof in a sample of bodily fluid of said patient,
= comparing said level of pro-Adrenomedullin or fragment thereof to a pre-
determined threshold or a previous level of pro-Adrenomedullin or fragment
thereof, and
= correlating said level of pro-Adrenomedullin or fragment thereof with the
risk
of life-threatening deterioration or an adverse event, or
= correlating said level of pro-Adrenomedullin or fragment thereof with the

severity, or
= correlating said level of pro-Adrenomedullin or fragment thereof with the

success of a therapy or intervention,
wherein said pro-Adrenomedullin or fragment thereof is selected from the group
consisting of
PAMP (SEQ ID No. 32), MR-proADM (SEQ ID No. 33), ADM-NH2 (SEQ ID No. 20), ADM-
Gly (SEQ ID No. 21) and CT-proADM (SEQ ID No. 34).
Subject matter of the present invention is an Anti-adrenomedullin (ADM)
antibody or anti-
ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy or
intervention in a
patient in a patient infected with a Corona virus.


Related patent documents